InMed Pharmaceuticals annual return on equity
2021
2022
2023
2024
2025
InMed Pharmaceuticals Return on Equity (ROE) Growth & History (INM)
InMed Pharmaceuticals's return on equity was −72.10% for fiscal 2025.
View full InMed Pharmaceuticals company overviewInMed Pharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-06-30 | −72.10% | −0.02 pp |
| 2024 | 2024-06-30 | −72.08% | +3.00 pp |
| 2023 | 2023-06-30 | −75.09% | +150.98 pp |
| 2022 | 2022-06-30 | −226.07% | −72.12 pp |
| 2021 | 2021-06-30 | −153.95% | — |
InMed Pharmaceuticals quarterly return on equity
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q3 2026 | 2026-03-31 | −36.00% | −3.87 pp |
| Q2 2026 | 2025-12-31 | −19.15% | +16.17 pp |
| Q1 2026 | 2025-09-30 | −13.80% | +5.26 pp |
| Q4 2025 | 2025-06-30 | −17.48% | +0.15 pp |
| Q3 2025 | 2025-03-31 | −32.13% | — |
| Q2 2025 | 2024-12-31 | −35.33% | +57.23 pp |
| Q1 2025 | 2024-09-30 | −19.06% | +182.94 pp |
| Q4 2024 | 2024-06-30 | −17.63% | −14.87 pp |
| Q2 2024 | 2023-12-31 | −92.56% | −75.98 pp |
| Q1 2024 | 2023-09-30 | −202.01% | −167.06 pp |
| Q4 2023 | 2023-06-30 | −2.76% | +76.07 pp |
| Q3 2023 | 2023-03-31 | −14.95% | +12.79 pp |
| Q2 2023 | 2022-12-31 | −16.58% | +12.56 pp |
| Q1 2023 | 2022-09-30 | −34.95% | −8.65 pp |
| Q4 2022 | 2022-06-30 | −78.84% | −42.20 pp |
| Q3 2022 | 2022-03-31 | −27.75% | +6.71 pp |
| Q2 2022 | 2021-12-31 | −29.15% | +7.99 pp |
| Q1 2022 | 2021-09-30 | −26.30% | +4.53 pp |
| Q4 2021 | 2021-06-30 | −36.63% | — |
| Q3 2021 | 2021-03-31 | −34.45% | — |
| Q2 2021 | 2020-12-31 | −37.13% | — |
| Q1 2021 | 2020-09-30 | −30.83% | — |
InMed Pharmaceuticals return on equity trends
Between the periods ended 2021-06-30 and 2025-06-30, InMed Pharmaceuticals's return on equity increased from −153.95% to −72.10%, a change of +81.85 percentage points. The latest reported quarter, Q3 2026, shows −36.00%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review InMed Pharmaceuticals source filings ↗